Article info

Download PDFPDF
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis

Authors

  • Koichi Takeda Department of Onco-Rheumatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan Department of Infectious Diseases, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Noriko Yanagitani Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Koichi Takeda, Department of Onco-Rheumatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; koichi.takeda{at}jfcr.or.jp
View Full Text

Citation

Takeda K, Yanagitani N
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis

Publication history

  • Received April 8, 2022
  • Accepted May 12, 2022
  • First published May 19, 2022.
Online issue publication 
September 12, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.